Syzygy Plasmonics has tested its all-electric CO2-to-fuel production technology. Photo courtesy of Syzygy

Houston-based clean energy company Syzygy Plasmonics has successfully tested all-electric CO2-to-fuel production technology at RTI International’s facility at North Carolina’s Research Triangle Park.

Syzygy says the technology can significantly decarbonize transportation by converting two potent greenhouse gases, carbon dioxide and methane, into low-carbon jet fuel, diesel, and gasoline.

Equinor Ventures and Sumitomo Corp. of Americas sponsored the pilot project.

“This project showcases our ability to fight climate change by converting harmful greenhouse gases into fuel,” Trevor Best, CEO of Syzygy, says in a news release.

“At scale,” he adds, “we’re talking about significantly reducing and potentially eliminating the carbon intensity of shipping, trucking, and aviation. This is a major step toward quickly and cost effectively cutting emissions from the heavy-duty transport sector.”

At commercial scale, a typical Syzygy plant will consume nearly 200,000 tons of CO2 per year, the equivalent of taking 45,000 cars off the road.

“The results of this demonstration are encouraging and represent an important milestone in our collaboration with Syzygy,” says Sameer Parvathikar, director of renewable energy and energy storage at RTI.

In addition to the CO2-to-fuel demonstration, Syzygy's Ammonia e-Cracking™ technology has completed over 2,000 hours of performance and optimization testing at its plant in Houston. Syzygy is finalizing a site and partners for a commercial CO2-to-fuel plant.

Syzygy is working to decarbonize the chemical industry, responsible for almost 20 percent of industrial CO2 emissions, by using light instead of combustion to drive chemical reactions.

------

This article originally ran on EnergyCapital.

With this new joint effort, Syzygy is one step closer to commercial scale of its decarbonization technology. Photo courtesy of Syzygy

Houston startup teams up with nonprofit research for decarbonization pilot

seeing green

A Houston tech company has joined forces with a nonprofit to test a new sustainable fuel production process.

The project is a joint effort from Houston-based Syzygy Plasmonics and nonprofit research institute RTI International and sponsored by Equinor Ventures and Sumitomo Corporation of Americas. Based in the RTI facility in Research Triangle Park, North Carolina, the six-month pilot is testing a way to convert two potent greenhouse gases — carbon dioxide (CO2) and methane (CH4) — into low-carbon-intensity fuels, which have the potential to replace petroleum-based jet fuel, diesel, and gasoline.

"This demonstration will be the first of its kind and represents a disruptive step in carbon utilization. The sustainable fuels produced are expected to quickly achieve cost parity with today's fossil fuels," says Syzygy CEO Trevor Best in a news release. "Integrating our technology with RTI's Fischer-Tropsch synthesis system has the potential to significantly reduce the carbon intensity of shipping, trucking, and aviation without requiring major fleet modifications."

According to Syzygy, the pilot is a step toward being able to scale the process to a commercial-ready Syzygy e-fuels plant.

"By making minor adjustments in the process, we also expect to produce sustainable methanol using the same technology," Best continues.

An independent research institute, RTI International's focus is on improving the human condition. The multidisciplinary nonprofit seeks to support science-based solutions like Syzygy's technology, which has already proven its scale-up capabilities in earlier testing.

Through the partnership, RTI will assist Syzygy with process design and systems integration for the pilot-scale demonstration. Once it reaches commercial scale, the technology is expected to turn millions of tons of CO2 per year to produce sustainable fuels.

"We are excited about the opportunity to collaborate with Syzygy to test and assist in the scale-up of this promising technology," says Sameer Parvathikar, Ph.D., the director of the Renewable Energy and Energy Storage program in RTI's Technology Advancement and Commercialization business unit. "This work aligns with our capabilities, our goals of helping de-risk and commercialize novel technologies, and our vision to address the world's most critical problems with science-based solutions."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston innovator makes leap into VC to boost representation in the boardroom

Houston innovators Podcast episode 260

When Aileen Allen was contemplating a big career move — swapping sides of the table from tech company to venture investor — she was motivated by driving gender and experience diversity amongst decision makers.

"I've worked for VC-backed companies for most of my career and had the opportunity as an executive to be in the boardroom during that time," she says on the Houston Innovators Podcast. "One of my takeaways was that very few of my board members looked like me. I had one or two women on any of my boards at a time in totality, and very few of my board members had been operators."

"I'd really like to change that, and I'd like there to be better representation and diversification in the boardroom," she adds.

But Allen didn't just jump feet first into the career change. She did her homework first, spending months talking to mentors, meeting investors for over 30 informational interviews, and compiling everything she learned. She says she learned how different the world of VC is compared to her time as an operator — from the unstructured workflow at a VC firm to hustle mentality you have as an operator.

This summer, she made the jump and joined Mercury as venture partner. She just recently closed her first deal for the Houston VC firm that focuses on B2B SaaS startups. She also is on the board of the Houston Angel Network and is working with leadership to grow and expand membership.

A native Houstonian, Allen spent a large chunk of her career in the Bay Area, which her most significant role at Atlassian where she oversaw product marketing as the company scaled. When she relocated back to Houston — by way of a few years in Austin's tech scene — she says she struggled at first to find Houston's entrepreneurial ecosystem.

"I think my first impression (of Houston's tech ecosystem) was, 'where is it?'" she says, adding for context that that she did relocate in 2020 when the pandemic greatly affected events and activity. "It feels like there's something that's happening in Houston, but it's smaller or maybe a bit more fragmented, and I think there's an opportunity for a lot of us on the investing side and founders who have had successful exits or are running companies at scale to do more and give back in more meaningful ways to create the presence that Austin and the Bay Area is really known for."

Houston biotech startup secures $10M seed round to propel cancer-fighting therapy from bench to bedside

fresh funding

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT.

The company is working on the next-generation of antibody-drug conjugates (ADC) therapeutics that process dual payloads as targeted treatments for a set of challenging cancers. The innovative treatment is based on research from UTHealth experts Dr. Kyoji Tsuchikama and Dr. Zhiqiang An.

“Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments," Torres continues.

He explains that the funding will toward advancing CrossBridge's first development candidate, CBB-120, into preclinical non-GLP toxicology studies in addition to derisking the company’s proprietary linker technology with dual-payload applications, per the release.

As a result of the raise, William McKeon, president and CEO of the Texas Medical Center, and Damir Illich, manager of life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” McKeon says in the release. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”

Houston firm scores 2 grants to support testing treatment for addiction, neurodegenerative diseases

money moves

A Houston organization devoted to developing early-stage therapeutic and medical device technologies announced fresh funding for one of its startups.

Fannin Partners' Goldenrod Therapeutics, received a $320,000 Phase I SBIR grant from the National Institute on Drug Abuse (NIDA) for studies regarding both addiction medicine and neurodegenerative diseases with a single lead candidate, called 11h.

The grant will fund studies in rodent models of methamphetamine addiction and the efficacy of 11h for the tiny patients. This is the next step in charting the established promise of 11h in substance use disorders using animal models. Existing therapies for opioid and alcohol addiction have high relapse rates, and there are currently no FDA-approved medications for Stimulant Use Disorders (StUDs).

Previous preclinical studies demonstrated that 11h was effective in the fight against cocaine addiction. The goal is to note similar results in methamphetamine addiction.

At the same time, Fannin was also granted a $250,000 Early Hypothesis Development Award from the Department of Defense (DoD) to study 11h in neurodegenerative diseases. Specifically, the funds will be used to work on rodent models of multiple sclerosis (MS).

Fannin’s goal is to develop an oral medication that slows or reverses the progression of MS, while also improving the patient’s quality of life by relieving symptoms. Many MS medications come with the threat of liver injury and increased risk of infection, so sidestepping those is also a hope for 11h.

In fact, 11h was developed to minimize the toxicities associated with existing PDE4 inhibitors. Early evidence shows that the drug is not only effective, but also safe and easily tolerable.

“NIDA’s continued support of our SUD program highlights the potential of 11h to significantly improve the standard of care for patients suffering from these conditions, some of which lack any approved pharmaceutical options," says Dr. Atul Varadhachary, managing partner at Fannin, in a news release. “The additional DoD funding will allow us to explore 11h’s impact on neurodegenerative disease, as well. We are grateful for the support from both organizations as we advance 11h towards clinical development.”

Previous steps in 11h’s development were funded by a $350,000 Phase I SBIR grant from NIDA. 11h is part of NIDA’s Addiction Treatment Discovery Program. Next year, Fannin will likely scale up Good Manufacturing Practices (GMP) production and complete toxicology studies. This will lead to clinical trials for 11h for cocaine use disorder and other StUDs. But don’t expect Fannin to be quiet for long. Its next big discovery is always on the horizon.